Literature DB >> 35544355

Practice-changing publications: Kidney cancer.

Luke T Lavallée1, Anil Kapoor2.   

Abstract

Entities:  

Year:  2022        PMID: 35544355      PMCID: PMC9119591          DOI: 10.5489/cuaj.7862

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   2.052


× No keyword cloud information.
  12 in total

1.  Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial.

Authors:  Rodney H Breau; Dean A Fergusson; Greg Knoll; Kristen McAlpine; Christopher Morash; Sonya Cnossen; Luke T Lavallée; Ranjeeta Mallick; Antonio Finelli; Michael A S Jewett; Bradley C Leibovich; Jonathan A Cook; Anil Kapoor; Frederic Pouliot; Jonathan Izawa; Ricardo Rendon; Ilias Cagiannos
Journal:  J Urol       Date:  2020-12-21       Impact factor: 7.450

2.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

3.  Shared decision-making for the management of small renal masses - development and acceptability testing of a novel patient decision aid.

Authors:  Kristen McAlpine; Rodney H Breau; Dawn Stacey; Christopher Knee; Michael A S Jewett; Philippe D Violette; Patrick O Richard; Ilias Cagiannos; Christopher Morash; Luke T Lavallée
Journal:  Can Urol Assoc J       Date:  2020-06-16       Impact factor: 1.862

4.  Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.

Authors:  Christina Canil; Anil Kapoor; Naveen S Basappa; Georg Bjarnason; Dominick Bossé; Shaan Dudani; Jeffrey Graham; Samantha Gray; Aaron R Hansen; Daniel Y C Heng; Pierre I Karakiewicz; Christian Kollmannsberger; Aly-Khan A Lalani; Scott A North; François Patenaude; Denis Soulières; Myuran Thana; Eric Winquist; Lori A Wood; M Neil Reaume; Ranjena Maloni; Sebastien J Hotte
Journal:  Can Urol Assoc J       Date:  2021-04       Impact factor: 1.862

5.  Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Piotr Tomczak; Se Hoon Park; Balaji Venugopal; Thomas Ferguson; Yen-Hwa Chang; Jaroslav Hajek; Stefan N Symeonides; Jae Lyun Lee; Naveed Sarwar; Antoine Thiery-Vuillemin; Marine Gross-Goupil; Mauricio Mahave; Naomi B Haas; Piotr Sawrycki; Howard Gurney; Christine Chevreau; Bohuslav Melichar; Evgeniy Kopyltsov; Ajjai Alva; John M Burke; Gurjyot Doshi; Delphine Topart; Stephane Oudard; Hans Hammers; Hiroshi Kitamura; Jens Bedke; Rodolfo F Perini; Pingye Zhang; Kentaro Imai; Jaqueline Willemann-Rogerio; David I Quinn; Thomas Powles
Journal:  N Engl J Med       Date:  2021-08-19       Impact factor: 91.245

6.  Evidence-based Urology: Surrogate Endpoints - Con.

Authors:  Kristen McAlpine; Luke T Lavallée; Rodney H Breau
Journal:  Eur Urol Focus       Date:  2021-10-23

7.  Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Authors:  Eric Jonasch; Frede Donskov; Othon Iliopoulos; W Kimryn Rathmell; Vivek K Narayan; Benjamin L Maughan; Stephane Oudard; Tobias Else; Jodi K Maranchie; Sarah J Welsh; Sanjay Thamake; Eric K Park; Rodolfo F Perini; W Marston Linehan; Ramaprasad Srinivasan
Journal:  N Engl J Med       Date:  2021-11-25       Impact factor: 176.079

8.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

9.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Authors:  Robert Motzer; Boris Alekseev; Sun-Young Rha; Camillo Porta; Masatoshi Eto; Thomas Powles; Viktor Grünwald; Thomas E Hutson; Evgeny Kopyltsov; María J Méndez-Vidal; Vadim Kozlov; Anna Alyasova; Sung-Hoo Hong; Anil Kapoor; Teresa Alonso Gordoa; Jaime R Merchan; Eric Winquist; Pablo Maroto; Jeffrey C Goh; Miso Kim; Howard Gurney; Vijay Patel; Avivit Peer; Giuseppe Procopio; Toshio Takagi; Bohuslav Melichar; Frederic Rolland; Ugo De Giorgi; Shirley Wong; Jens Bedke; Manuela Schmidinger; Corina E Dutcus; Alan D Smith; Lea Dutta; Kalgi Mody; Rodolfo F Perini; Dongyuan Xing; Toni K Choueiri
Journal:  N Engl J Med       Date:  2021-02-13       Impact factor: 91.245

10.  Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

Authors:  Laurence Albiges; Nizar M Tannir; Mauricio Burotto; David McDermott; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Thomas Powles; Frede Donskov; Saby George; Christian K Kollmannsberger; Howard Gurney; Marc-Oliver Grimm; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Toni K Choueiri; Shruti Shally Saggi; M Brent McHenry; Robert J Motzer
Journal:  ESMO Open       Date:  2020-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.